Latest / MD Longevity Lab: Playing the Long Game with Drs. Vikas and Nisha Patel / 19. Biological Aging Clocks, mTOR & Rapamycin: A Reality Check with Dr. Matt Kaeberlein
Transcript
- 0:04Welcome to MD Longevity Lab, where we're playing the long
- 0:06game. This is a podcast where science
- 0:09meets real life, with expert insights, practical tips, and
- 0:12real world tools to not only live longer, but live better.
- 0:17Our aim is to radically change the way medicine is practiced
- 0:20and enable individuals to age gracefully, maintaining health,
- 0:24span and vitality well into their later years.
- 0:27We're your host doctor, Nisha and Dr. Vikas Patel, physicians,
- 0:31partners in life, and parents, balancing work, Wellness and
- 0:35everything in between. Let's dive in.
- 0:42Welcome back to the MD Longevity Lab podcast, Playing the long
- 0:46game. I'm Doctor Nisha Patel.
- 0:49And I'm Doctor Vikas Patel. Today is a special one because
- 0:53we're joined by somebody who has probably influenced every
- 0:56longevity conversation happening today, at least to some degree,
- 1:00whether people realize it or not.
- 1:02He's a scientist whose work has shaped how we think about aging,
- 1:05health, span, mtor, and maybe one of the most misunderstood
- 1:10medications in the longevity space, rapamycin.
- 1:13We are talking about none other than Doctor Matt Cabeline.
- 1:17He is a world leading scientist in the biology of aging.
- 1:22He notably completed his PhD from MIT in a mere 4 years and
- 1:27three months. I think at the top of this
- 1:29class, he's also the founder of Opti Span, which is a health
- 1:34span and longevity focused clinic, a very similar to what
- 1:37we do at MD Longevity lab focused a lot on preventive
- 1:41medicine. He is the former director of the
- 1:45Healthy Aging and Longevity Research Institute at the
- 1:48University of Washington. His research work has really
- 1:52shaped much of our modern understanding of a few things
- 1:56that we'll get into in the podcast today, including mtor,
- 1:59Rapamycin, just translational geoscience.
- 2:02And he did some of this work initially starting at MIT while
- 2:06identifying some of the genes responsible for aging in yeast.
- 2:12He is also notably the Co founder of the dog aging Project
- 2:16and I believe parent to three dogs currently.
- 2:21And then something that we, Nisha and I, have really enjoyed
- 2:25is that he's really a scientist who's known for nuance,
- 2:28integrity, and really elevating evidence over the hype and the
- 2:33longevity space, which is a common pitfall or trap that we
- 2:37see quite frequently. You are one of our favorite
- 2:40people because you tell the truth even when it's
- 2:44inconvenient. And so we are so excited to dive
- 2:47into longevity through the lens of someone who really
- 2:50understands the science. Matt, thank you so much for
- 2:52being here. Well, thank you for that kind
- 2:55introduction that that was that was really nice and appreciated.
- 2:58And it's a pleasure to be able to join you today.
- 3:01I'm looking forward to it. So we're going to get started
- 3:04with a couple basics here. I wanted your take on what you
- 3:10think the biggest shift is going to be and how we define and
- 3:14measure health span in the coming decades.
- 3:18Sure. I mean, I think maybe the way I
- 3:21would start the conversation is that I think of health span as a
- 3:26really useful concept. I'm not really sure that we
- 3:30should try to measure health span.
- 3:33And what I mean by that is I think even to some extent when
- 3:35we talk about trying to measure health span, the word itself is
- 3:38a little bit problematic because because of that span piece,
- 3:41right? It implies that there is a time
- 3:44or a length to health, which implies that before an
- 3:47individual health goes from something you have to something
- 3:51you don't have overnight. And of course, that's not the
- 3:52reality for anyone, right? So I think maybe the way we
- 3:57should think about it is that health span is multifactorial.
- 4:01It's made-up of lots of different aspects of function
- 4:05and emotional health and molecular biomarkers that we
- 4:09are, I think becoming better able to assess each of each of
- 4:14those individually and understand what they mean and
- 4:17then more importantly, what what to do about it.
- 4:19So I think the way that I see health span changing going
- 4:24forward, and I think we're already starting to see this is,
- 4:26is #1A better, a more widespread recognition of how important it
- 4:32is to take a proactive approach to health, right?
- 4:35And to get ahead of health and not wait until people are sick
- 4:39before we try to do anything about it.
- 4:41So proactive preventative approaches, I think are going to
- 4:43continue to become an emphasis going forward.
- 4:46And then I think also as the tools become better developed
- 4:50and as AI gets integrated, we're going to continue to see real
- 4:54opportunities for personalized approaches to health span
- 4:58extension or health promotion. And I think this is something
- 5:02that a lot of people have been excited about for a long time,
- 5:04the idea of personalized medicine to date that has really
- 5:08been fairly rudimentary. And we don't have a lot of
- 5:11concrete examples of how this can be done well.
- 5:13But I think, you know, with the new AI tools that are coming
- 5:16online and with the sort of plethora of, of new diagnostics
- 5:23that we have at our disposable at our disposal that there are
- 5:27real opportunities for true, we're starting to get towards
- 5:30personalized approaches to, to preventative healthcare.
- 5:32So I think that's that's probably the, those are the
- 5:35obvious things that are going to continue to get better and
- 5:38become widely implemented in the next 3-5 years looking forward.
- 5:43One thing I wanted to pick your brain about, there's so many of
- 5:46these direct to consumer biological age tests with no
- 5:51oversight, no medical oversight. We have our opinions on those,
- 5:55but I would love to hear your take on it.
- 5:57Sure. Yeah, I'm very opinionated about
- 5:59this topic. I will say, you know, I was just
- 6:01talking about the new tools, the new diagnostics that we have at
- 6:04our disposal to assess different aspects of health.
- 6:08I think the biological age tests sort of overlap with that, that
- 6:12set of of diagnostics in the sense that in the research world
- 6:16there has been a lot of progress at first of all understanding
- 6:20what are some of the things that we can measure that tell us
- 6:23about health, which is correlated to biological age,
- 6:26right? So there's been a lot of
- 6:28advances and I think the development of these biological
- 6:30aging clocks is what most people call them has been an important
- 6:33research advance for sure in the field.
- 6:35So first of all, it might be useful to just appreciate what a
- 6:38biological aging clock actually is fundamentally.
- 6:42So biological aging clocks are just a collection of individual
- 6:48biomarkers of aging and a biomarker of aging is just
- 6:51something that changes in a predictable way across the
- 6:54population with chronological age.
- 6:57OK. So there are tons of those like
- 6:58skin wrinkles, graying hair, testosterone levels in men, VO2
- 7:03Max, grip strength. You can see these things at
- 7:06molecular levels as well. Metabolites that change with
- 7:10age, proteins that change with age.
- 7:13All the clocks are is taking a bunch of those and using
- 7:17complicated math and usually machine learning to pick a
- 7:21subset of biomarkers, anywhere from a few dozen to a few 100.
- 7:26And then creating a linear equation where you weight each
- 7:29biomarker differently to give you a correlation to something
- 7:33that's associated with health. And that can either be
- 7:36chronological age, those are the generation one clocks, or it can
- 7:39be risk of dying, mortality risk, or risk of developing a
- 7:44age-related disease. Those are generation 2 clocks.
- 7:46So you're using a collection of biomarkers to create a
- 7:50predictive algorithm, a correlation to something of
- 7:53interest, chronological age, your birthday or your likelihood
- 7:57of dying or your likelihood of getting sick.
- 7:59That's what aging clocks are. And just for a little bit of
- 8:01nuance, there is a different flavor of aging clocks, which
- 8:04some people call generation 3 clocks, which instead of
- 8:07predicting chronological age or your risk of dying, predict the
- 8:12likelihood that your health is going to change over the next
- 8:15five years, 10 years. Those are called pace of aging
- 8:18clocks. So they're predicting the rate
- 8:19of change in health. OK, So these are conceptually
- 8:24really fascinating. I think in the research world
- 8:27have taught us a lot about the biology of aging and will
- 8:29continue to teach us a lot about the biology of aging.
- 8:32And they work pretty well at the population level.
- 8:34If you have data from 100,000 people, you can develop really
- 8:38good correlations. Where they don't work so, so
- 8:41well even in the research world, is at the individual level.
- 8:44So every measurement has some error associated with it.
- 8:47The best clocks have an error of, you know ±5 years, maybe a
- 8:52little bit less than that, maybe a little bit more than that.
- 8:54So that means the standard deviation from the true value
- 8:57for whatever they're estimating chronological age or risk of
- 9:00dying is going to be 5 years. So 2/3 of the time it'll be less
- 9:04than that, 1/3 of the time it'll be more than that.
- 9:06OK, so that's useful to understand.
- 9:08That's in the research world. Perfect conditions.
- 9:10The problem we've got is we've had a bunch of direct to
- 9:13consumer companies start selling these tests, marketing them to
- 9:16people. They're not doing these things
- 9:18under the most perfect conditions, and in fact, we have
- 9:21no idea what the error rates are.
- 9:23I mean, there are lots of problems with the direct to
- 9:25consumer test, but to my mind, that's the fundamental problem.
- 9:28You can't use them because you don't know what the error is.
- 9:31Period. Full stop.
- 9:33So when researchers have some sort of intervention and one way
- 9:37of doing these aging clocks are methylation tests for DNA and
- 9:42they seem to imply that their technology their when they have
- 9:47introduced some sort of intervention and they're
- 9:49tracking methylation trends on DNA that it does actually give
- 9:54them true insight. But then when we look at the
- 9:57consumer grade methylation test, it's kind of all over the place.
- 10:02Yeah. So a couple things to say there.
- 10:03Number one, yes, I think in the research world, there are are a
- 10:06small number of quality studies that have looked at the way
- 10:11these methylation clocks. And again, I know it's getting a
- 10:14little bit in the weeds, but it's probably worth
- 10:16appreciating. The epigenetic clocks or
- 10:19methylation clocks are just one flavor of aging clocks.
- 10:21They're the ones that were sort of first popularized and they're
- 10:24the ones that have been used the most in the research world.
- 10:27But you can develop comparable, maybe even more precise aging
- 10:32clocks using other types of biological data, chromium,
- 10:36metabolome, transcriptome, microbiome, maybe even or
- 10:40functional measures like I was alluding to grip strength and
- 10:43VO2 Max and body composition. So the epigenetic or methylation
- 10:46clocks are just one flavor, but they are the most common flavor.
- 10:49So you're right, there are studies that have been
- 10:52published, many studies that have been published that
- 10:54correlate changes in these epigenetic clocks to
- 10:57interventions. They could be lifestyle
- 10:59interventions, drugs to major life events, pregnancy,
- 11:03menopause to environmental exposure.
- 11:06Some of those studies are high quality.
- 11:08The vast majority are low quality in my opinion.
- 11:10But there are lots of them out there and it's hard, I think for
- 11:13the average person. Certainly it's hard for me as a
- 11:15scientist, it takes me time to dive into the studies and really
- 11:18look at them to know which are high quality and which are low
- 11:21quality. So all of that is being said is
- 11:25that I think at the population level, when done well, these
- 11:28clocks can actually tell you something about how and
- 11:32environmental change, a major life event, stressful event,
- 11:35maybe even medications or lifestyle interventions are
- 11:40impacting the underlying aging biology.
- 11:43But it's an indirect estimate of aging biology.
- 11:46I think that's the other thing that's worth appreciating.
- 11:49If you ever hear anybody say, and I guarantee if you stay in
- 11:52the space long enough, you will you ever hear anybody say I
- 11:57measured biological age using this test, They either A, don't
- 12:01understand how the test works or B, they are intentionally
- 12:04telling you something that is not true and you can consider
- 12:07how you feel about that. I know how I feel about that.
- 12:10Biological aging clocks do not measure biological age.
- 12:13They measure either average methylation state at a subset of
- 12:17sites or protein, protein abundances or transcript
- 12:21abundances or whatever it is they're measuring.
- 12:23It's not biological age. And those are correlated to what
- 12:26they're estimating, which is also not biological age.
- 12:29It's chronological age or mortality risk or risk of
- 12:33developing cancer. So there's a lot of, I think,
- 12:36sloppy language and misunderstanding around what
- 12:39these tests actually do, how they work and whether or not you
- 12:42can you can rely on them. Again, my biggest concern is
- 12:47that in the direct to consumer space, all bets are off because
- 12:50we just don't know what the error rate is for what the tests
- 12:55are supposed to be estimating. Most of the direct to consumer
- 12:58tests are estimating mortality risk.
- 13:00Those are the algorithms that they use, which is fine.
- 13:03If we had it, if we, if we knew what the error rate was, if we
- 13:05knew that was ±5 years, then we could put statistical bounds on
- 13:10the test and we could say, OK, with a 66% probability, a change
- 13:16of more than five years is meaningful, right?
- 13:19But we don't know what the error rates are.
- 13:20My intuition based off of some evidence is that the error rates
- 13:24are much greater than five years.
- 13:26And for people who are interested, like if you're a, if
- 13:28you're a data nerd, I would just suggest if you want to, if you
- 13:31want to do an interesting thought experiment, because a
- 13:33lot of people are say buying these tests quarterly and taking
- 13:36them quarterly, right? If you want to do an interesting
- 13:38thought experiment, whatever your age is, think about your
- 13:42age. Put that into ChatGPT and say
- 13:44give me a set of 10 series of four numbers based off of a
- 13:48normal distribution at whatever your age is.
- 13:51Let's say you're 50, around 50 with a standard deviation of
- 13:54five. That's the result you would get
- 13:58by chance if you did these tests four times quarterly, right?
- 14:03And you're you did everything right, your biological age
- 14:05didn't move. And look at the look at the
- 14:08distribution. You're going to look at that and
- 14:10then think about what you would think if you got those results
- 14:12back from your biological age test.
- 14:14It's all over the map. These things in my view are
- 14:16completely useless at this point and that's the best case
- 14:20scenario. I guarantee you the error rate
- 14:23is more than five years on any direct to consumer facing
- 14:26biological age test today. You.
- 14:27Know you did the methylation test on yourself the same day,
- 14:30right? Same company?
- 14:31And what were your results? Yeah.
- 14:34So I mean, it's complicated the way I did the experiment.
- 14:36But basically what I did was I did 4 different companies.
- 14:39I did each test in duplicate and it was same sample, same days.
- 14:42Some of the companies use saliva, some of these them use
- 14:45blood, which makes it more complicated.
- 14:46But it was the same samples and the results were, I think,
- 14:50interesting and informative. For three of the companies, the
- 14:53two replicates were relatively close together within five years
- 14:56of each other. When you look across the four
- 14:57companies, the spread was more than 20 years and for one
- 15:02company the spread was almost 20 years.
- 15:04It was like 15 years for the two replicates.
- 15:06So again, first of all, it's not, it's not a large enough
- 15:10set, like 2 replicates isn't a large enough set for me to say
- 15:13anything other than there's a lot of noise in the system.
- 15:16And when you look across the industry, it's a complete
- 15:19freaking mess. It's my take home from that
- 15:21experiment. I think in some ways that
- 15:23experiment was good because it brought attention and can people
- 15:26can point to it. But it's also a little bit
- 15:27distracting in that you don't even need to do the experiment.
- 15:30But if you're at all quantitatively inclined, that
- 15:33sort of mathematical thought experiment I just laid out, if
- 15:36you just, if you understand what a normal distribution is and
- 15:39what a standard deviation is, and that the magnitude of effect
- 15:43we're talking about, even in the very best case scenario, like
- 15:46the Horvath clock, the gold standard has an error of 3.6
- 15:50year. That's the very, very best
- 15:52you're ever, ever, ever, ever going to get and it's still 3.6
- 15:56standard deviation. So if you understand that and
- 15:59you model it, you will very quickly realize how useless
- 16:02these tests are right now at the individual level.
- 16:04Because I'm telling you in the direct to consumer space, the
- 16:07error rate is at least three times what it is for the
- 16:09Horvath. I think that's reassuring and
- 16:12it's a good number for our patients that you just can't
- 16:15panic over a single number that you get from these things.
- 16:19I think we feel a couple phone calls or inquiries every week on
- 16:25a patient who specifically asks us, do we run these tests?
- 16:29And then we have to go into this lengthy explanation, as you just
- 16:32behaved about why this may not be a test that's worth us, worth
- 16:36your time. And there's so many more useful
- 16:38tests, right? VO2 Max you're.
- 16:40Absolutely. Dexapan.
- 16:42So I think that's really the important message, right, is
- 16:46that we have really informative and actionable biomarkers.
- 16:50Of course people want to get to a single number.
- 16:52I understand the desire for that.
- 16:54But I think it's just, it's not nearly as useful as looking at a
- 16:57collection of of health related biomarkers that span the
- 17:01different systems of health. So you can really get a feel
- 17:04for, for where the biggest opportunities are.
- 17:06It might be worth saying the the one type of aging clock I'm
- 17:10relatively bullish on right now are these clinical chemistry
- 17:13clocks like Lin age 2 or Enable age that use things that we can
- 17:19measure from blood or urine and go to to reference laboratories
- 17:24like LabCorp or Quest. I think those are quite
- 17:26powerful. They're trained on mortality.
- 17:28And what you can get is you can get from that a picture of for a
- 17:33given individual, which biomarkers, if you can move them
- 17:38are most likely to move the risk for mortality.
- 17:41And that makes the assumption, of course, that these things are
- 17:44faithfully representing mortality risk.
- 17:46But when the biomarkers are directionally consistent with
- 17:51what we've learned from decades of clinical practice, it makes
- 17:55sense, right? If you take the Lineage 2 test
- 17:58and it tells you that for you, you're going to get the biggest
- 18:01effect on mortality risk. If you get your blood pressure
- 18:04under control and your A1C, those are the things you can
- 18:08focus on right away. And so there I think those tests
- 18:12are potentially valuable because they give you actionable
- 18:14insights that are potentially also behavior modifying.
- 18:17You can talk to a patient and say, look, this algorithm is
- 18:21telling us that for you, it's most likely if we fix these
- 18:24things, you're going to have a big impact on your risk of dying
- 18:27or your risk of developing cancer.
- 18:28What whatever the case is that those are the kinds of tests I
- 18:31like because number one, we do know what the error is because
- 18:34we know what the error rate is for each of those individual
- 18:36measurements. Those reference laboratories are
- 18:39required by regulatory bodies to be within a certain tolerance
- 18:43for error. So, so they're clinically
- 18:45validated, we know the error rates and they're actionable.
- 18:47And I think those are the two pieces we need to get in place
- 18:50for the other aging clocks before they can reliably be used
- 18:54in a clinical setting. I think that's exciting.
- 18:57I think leveraging AI, which we'll talk a little bit about
- 19:01later by feeding at these biomarkers and figuring out
- 19:04because we do have data on, hey, if your hemoglobin A1C is 8.3,
- 19:10right, from a mortality standpoint, what does that mean
- 19:13for you? How much, how much higher
- 19:16mortality rate do you have at that A1C versus that 6.0?
- 19:21And I, so I think that's where these tests are looking
- 19:25promising. And it's very interesting what
- 19:26you bring up. I'd like to get into a little
- 19:28bit more of things that you specialize in, and this may be a
- 19:32little bit new to some of the listeners, but I'd like to see
- 19:36if you could explain to them what mtor is and why it's so
- 19:40central to aging biology. Sure.
- 19:43So I think from a very high level, you can think of mtor as
- 19:49sort of a gatekeeper for the cell and and and in terms of
- 19:53sensing the environment and making the fundamental decision,
- 19:56is the environment appropriate for growth and reproduction.
- 20:00OK. Mtor is a protein that that
- 20:02helps the cell makes make that decision and it's one of the key
- 20:05players in that decision. And that's a really important
- 20:07decision if you think about evolutionary time scales.
- 20:10Every Organism that has ever existed has had to make that
- 20:13decision since the environment and then determine is it a good
- 20:16time to grow and reproduce or is it better to shut down growth
- 20:20and become stress resistant and wait for the environment to
- 20:22improve. And then if you think about what
- 20:24in the environment helps inform that decision, it's a pretty
- 20:27small number of key factors that inform that decision.
- 20:31Temperature is going to be important.
- 20:33If it's an oxygen consuming Organism with mitochondria,
- 20:36oxygen abundance is going to be important and food is going to
- 20:40be important. And Tor senses all of those, but
- 20:43it is mostly interested in food. So it's a lot of people will
- 20:47call it a nutrient responsive sensor.
- 20:50So when nutrient levels are high, Tor gets active invaded
- 20:53and that tells the cell, OK, this is a good time to have
- 20:56babies because you have lots of food to feed them.
- 20:58When nutrient levels are low, that turns down Tor and that
- 21:02tells the cell, OK, let's shut down growth and reproduction.
- 21:05Let's become stress resistant and hope the environment gets
- 21:08better in the future. So that's basically what Tor
- 21:10does. It's a nutrient responsive
- 21:12kinase is the the biochemical term.
- 21:14And that just means that it puts phosphate groups on other
- 21:17proteins and controls signaling. So it's a signaling molecule
- 21:20that senses the environment and then signals growth versus
- 21:24reproduction versus stress resistance.
- 21:26A lot of people got interested in in Tor, you know, many years
- 21:30ago as an anti cancer target because it's so involved in cell
- 21:34division, right growth. And so people began studying it
- 21:36for anti cancer purposes. It actually got FDA approved.
- 21:41The drug that targets Tor, which we'll probably talk about is
- 21:43called rapamycin. It's an inhibitor of Tor that
- 21:46actually got approved as an immune suppressant because
- 21:48immune cells are rapidly dividing when you get an
- 21:50infection. It's used to prevent organ
- 21:53transplant rejection in that context.
- 21:54So that that's how Tor got studied clinically.
- 21:57But sort of in parallel, several labs around 2003 kind of
- 22:03stumbled on Tor as an important target for longevity.
- 22:06And I was fortunate enough to be involved in in those studies as
- 22:09a postdoc where we were working in yeast.
- 22:13I was working with Brian Kennedy and Stan Fields at this point,
- 22:16but other people were working in C elegans and Sydney Brenner's
- 22:20lab and Pankaj Kapahi were working in fruit flies.
- 22:23Again, this happens in science sometimes completely
- 22:25independently, completely different lines of research.
- 22:28We all converged on tour as being a central regulator of
- 22:32lifespan in each of those organisms.
- 22:34And I think, you know, 4 papers came out within a year of each
- 22:37other, all pointing to tour as regulating lifespan in three
- 22:41different organisms that are separated by billions of years
- 22:43of evolution. People paid attention because
- 22:45it's like, wow, this seems to be really important.
- 22:47And what we've learned since then is that that also is seems
- 22:50to be the case in mammals. So mice and rats and some
- 22:54evidence even in non human primates that when you turn down
- 22:56Tor, you slow aging, the animals live longer.
- 22:59Not only that, but they seem to be healthier.
- 23:02So turning down Tor preserves function in pretty much every
- 23:06tissue and organ where people have looked in mammals like mice
- 23:10and rats. So it really seems like Tor is a
- 23:14highly evolutionarily conserved, really important component of
- 23:19the biological aging network. And when we turn it down, as
- 23:22long as we don't turn it down too far, we can slow aging and
- 23:25increase lifespan, at least in laboratory animals.
- 23:27And I think obviously one of the big questions is, is it, does it
- 23:31work the same way in the real world?
- 23:32Could we do the same thing in people or you mentioned I'm, I,
- 23:34I'm part of the dog aging project.
- 23:36We're interested in knowing whether we can have a positive
- 23:39impact on our life lifespan and health span of our companion
- 23:41animals as well. So that's kind of the unknown
- 23:43and that's the frontier right now is to what extent can we
- 23:46modulate them toward a slow aging outside of a laboratory.
- 23:50We know rapamycin is an immunosuppressant.
- 23:54If you ask most physicians, I think they're clueless when it
- 23:57comes to rapamycin in the longevity space.
- 24:00Yeah, sure. And I mean, again, absolutely,
- 24:02that was the case five years ago.
- 24:04I think almost every doctor I talked to was like, why would
- 24:06you even think about giving an immunosuppressant to a healthy
- 24:09person? That's crazy.
- 24:10So now I think that's changing. People have at least heard of
- 24:12it. But I think you're right.
- 24:13Still, there's a lot of misperception and
- 24:15misunderstanding about about rapamycin.
- 24:18So again, rapamycin is a small molecule inhibitor of M Tor.
- 24:22So rapamycin turns down M Tor and in many ways you can think
- 24:26of it as tricking the cell or the Organism into thinking
- 24:29there's not very much food around because when you turn,
- 24:32when there's when there's low nutrients, that also turns down
- 24:34M Tor. So, so rapamycin turns down M
- 24:36Tor even when there's lots of food around it.
- 24:38It inhibits growth and cell division.
- 24:41As I alluded to, it was first developed clinically and FDA
- 24:46approved to prevent organ transplant rejection at high
- 24:51doses in people taking other immunosuppressants.
- 24:55Rapamycin has immunosuppressant properties and will reduce the
- 24:59likelihood of rejection of an implanted organ.
- 25:02That's what it was approved for. It works well in that capacity.
- 25:06Also in that context, there are side effects associated with
- 25:09rapamycin. They're not terrible, but it's
- 25:12got a black box warning. It's got some bad reputation
- 25:15associated with it because of the way it was developed,
- 25:18approved and used at high doses in these patients.
- 25:21I think the most common, the most common side effect is, is
- 25:24in organ transplant patients, significant mouth sores or, or
- 25:27ulcers in the mouth. But it also has some concerning
- 25:32side effects around what I would call pseudo diabetes.
- 25:35So something that looks like diabetes based on insulin
- 25:38sensitivity and and glucose measurements, high lipids,
- 25:41hyperlipidemia being one of the common side effects.
- 25:44And then of course people are worried about increased risk of
- 25:46infection because it's an immunosuppressant, right?
- 25:49So those are the things people get concerned about when you
- 25:51talk about using rapamycin in healthy people outside of the
- 25:55context of organ transplant. So why would you think about
- 26:00doing that? I mean, one reason is because of
- 26:02all of the evidence in laboratory animals that
- 26:04rapamycin can slow aging. Obviously that doesn't mean it's
- 26:06going to slow aging in people, but everything I know about
- 26:09biology tells me it's going to slow aging in people if we can
- 26:11get the dose dose right, slow biological aging.
- 26:14It is important to say just because something slows
- 26:17biological aging in people, that doesn't mean it's going to make
- 26:19you live longer and healthier if there are side effects that are
- 26:21going to offset the benefits. So to me that's I think there
- 26:25are two questions about rapamycin use off label at this
- 26:28point in my mind, 1 is what is the right dose, duration,
- 26:32frequency to get the beneficial effects on biological aging in
- 26:36people. Again, I can't prove it slows
- 26:37aging in people, but everything I know about biology tells me it
- 26:40will to some extent might not be as effective as it is in mice,
- 26:43but it's going to slow aging to some extent in people.
- 26:45OK, so how do we do that? What's the right dose, duration,
- 26:48all of that stuff And then are there going to be side effects
- 26:52at that dose, that duration, that regimen that are so
- 26:57counterproductive that it's not worth it even if you are aging
- 26:59more slowly? Those are the two questions I
- 27:01think we don't fundamentally know the answer to at this
- 27:04point. So what has evolved is a sort of
- 27:07off label use community that is centered around a certain dosing
- 27:14schedule. But the reality is lots of
- 27:17people are doing lots of different things.
- 27:19We don't have a ton of, I would say high quality, certainly not
- 27:24much, you know, double-blind, randomized placebo-controlled
- 27:27clinical trial level data yet to really be able to have a lot of
- 27:31confidence what people should be doing, what's effective, what's
- 27:34not effective. Happy to talk about what we do
- 27:37know. One thing I think it that is
- 27:38worth noting, and this is my, you know, largest frustration
- 27:42with rapamycin is unlike some other things, we don't have
- 27:46great biomarkers to use to tell us for you as an individual, if
- 27:52you're taking rapamycin, is it helping?
- 27:54Are you taking the right dose? We don't have obvious biomarkers
- 27:58that can tell us with a high degree of confidence that
- 28:00rapamycin is working for you. And if people don't know what I
- 28:04mean by that, I think as a a sort of interesting
- 28:06counterexample, another drug we can talk about if you want to
- 28:09are these things called SGLT 2 inhibitors, right?
- 28:11These are anti diabetes drugs. I'm sure you guys are very
- 28:14familiar with these drugs. Basically what they do is they
- 28:16cause you to pee out more glucose.
- 28:17They they reduce kidney reuptake by by the glucose.
- 28:20So it lowers your blood glucose because you're just getting it
- 28:22all out in your urine there. We've got really good
- 28:24biomarkers. We can measure fasting glucose
- 28:27levels, we can measure insulin sensitivity.
- 28:29So that's a case where there's a drug that also might have Jaro
- 28:33protective anti aging effects where we got a great biomarker
- 28:37or set of biomarkers to look at. So that to me is really the, the
- 28:40challenge with rapamycin right now is we don't have something
- 28:43like insulin sensitivity to look at and say we know we've got you
- 28:47dialed in with your rapamycin regimen.
- 28:49You took rapamycin for an injury, correct?
- 28:53That's right. Yeah.
- 28:54So I mean, if you had asked me, that was in 2020, so we're five
- 28:57years out now. But I mean, if you had asked me
- 28:59seven years ago, should people be taking Rapamycin off label?
- 29:03I would have been like, no, I don't think anybody should take
- 29:05Rapamycin off label. So I was a pretty conservative
- 29:07academic. Like it, that's, that's the way
- 29:09a lot of academics are, which is fine.
- 29:11Like the, I think there's, there's a right balance of
- 29:13conservatism and being willing to, to be risky, right, and, and
- 29:17figuring out that right risk reward ratio.
- 29:19But I had a personal experience where I, you know, after a long
- 29:23process of, of, you know, having this very painful shoulder
- 29:26condition that, that, that, you know, got to the point where I
- 29:29couldn't sleep, I couldn't go across the street and throw a
- 29:32ball with my son. I finally, and I was a pretty
- 29:34stereotypical, you know, 40 something year old man where I
- 29:38was like, I'm just going to it's I'm going to push through it.
- 29:40It's going to go away. I'm not going to go to the
- 29:42doctor, you know, and it didn't go away.
- 29:44It got worse. I finally got to the point I
- 29:47don't right thing. Yeah, so, so it was dumb.
- 29:51I I admit it was dumb, but anyways, it had to get to the
- 29:53point where I couldn't throw a ball with my son before I would
- 29:56go to the doctor and and say, OK, I need to get this fixed.
- 29:58Now I also like a stereotypical 40 something guy who thinks he
- 30:02knows a lot. I was sure I had a torn rotator
- 30:04cuff. So I go to my, I go to my
- 30:05primary care doctor and I'm like, I have a torn rotator
- 30:07cuff. I need you to give me a referral
- 30:09to a specialist so I can get it fixed.
- 30:11And he was like, no, I want you to go to physical therapy, blah,
- 30:13blah, blah. So I did that.
- 30:14That made it worse. So I went back to him and I'm
- 30:16like, OK, I tried it your way. Give me the referral to the
- 30:19specialist 'cause I need surgery to get this fixed.
- 30:21And so he did. And within like 5 minutes, the
- 30:24orthopedic specialist was like, you don't have a torn rotator
- 30:27cuff, you have adhesive capsulitis.
- 30:28And I was like, what is adhesive capsulitis?
- 30:31It's like it's called frozen shoulder.
- 30:32It's inflammation of the shoulder capsule.
- 30:35You know, it usually is more common in women than in men, but
- 30:38it happens in people your age. And I was like, my age, give me
- 30:41that stuff. So.
- 30:42And then, and then he's like, yeah, he's like, I want you to
- 30:46go back to physical therapy and maybe it'll go away in a year.
- 30:48And I was like, God, I can't live like this for a year.
- 30:52So, so I, I mean, I vividly remember I'm like in the car,
- 30:55I'm pissed off, I'm depressed. And I start thinking to myself,
- 30:58OK, this is an age-related inflammatory condition.
- 31:02At that time we were studying rapamycin in my lab.
- 31:04We'd shown that you could increase lifespan in mice with a
- 31:07three month treatment in old age.
- 31:09And then we gone on to looking at periodontal disease, which is
- 31:12an age-related inflammatory condition in the mouth.
- 31:14And we'd shown we had this data that treating old mice with
- 31:19rapamycin turned dramatically turned down inflammation in the
- 31:22oral cavity in the gums. And so I'm thinking to myself,
- 31:26OK, this is inflammation in the shoulder capsule.
- 31:28It's probably related to inflammation in the gums.
- 31:30Maybe rapamycin would work for my frozen shoulder.
- 31:33And again, I'm very lucky in the sense that I've got access to
- 31:37doctors who will work with me and were willing to prescribe me
- 31:43rapamycin so I could do this self experiment coming from, you
- 31:46know, a relatively informed place.
- 31:49And, you know, I can't 100% rule out placebo effect.
- 31:52All I can tell you is that within 10 weeks, I was 95% range
- 31:57of motion back and the pain was pretty much completely gone.
- 32:00And so it's such a biologically plausible mechanism that I, I
- 32:04really, it's hard for me not to believe that it was the
- 32:06rapamycin that, that had that effect.
- 32:08So that was my personal experience.
- 32:10And, but again, it took me having that personal situation
- 32:15to make the leap to, to try and rapamycin.
- 32:18I think before that I, and, and to be fair, we didn't have a lot
- 32:21of data on off label use of rapamycin in, you know, 2019,
- 32:25early 2020. Most of it came from the studies
- 32:27that Joan Manik didn't, that those might be worth talking
- 32:30about if, if you'd like to go into those.
- 32:32But outside of those clinical trials, we didn't have a lot of
- 32:34data on off label use of rapamycin.
- 32:36So we didn't really know what the risks look like at that
- 32:39point. I think now we know the risks
- 32:40when done, you know, in a way that is reasonable and that most
- 32:46people are using it. The risks seem very, very low at
- 32:48this point. It sounds like, and I, and I
- 32:50know that this has been explained for essentially like a
- 32:54lot of people even to this day, I'll get patients talk to me
- 32:58about fasting and the benefits of fasting and what it does to
- 33:03mtor. And it sounds like this is kind
- 33:05of the theory behind what rapamycin is doing, and people
- 33:08are trying to replicate it to some degree in these fasting
- 33:11states. I, I, yeah.
- 33:13So I, I think that's true. Again, fasting is a pretty
- 33:17misunderstood intervention, at least when you look at what we
- 33:21know from the biology of aging, right.
- 33:23And again, when we talk about is something a longevity
- 33:26intervention we don't have, we don't have the ability to prove
- 33:32definitively whether any intervention is a longevity
- 33:34intervention in people right outside of the things where we
- 33:37can say with a high degree of confidence, like don't smoke,
- 33:39you're more likely to live longer, eat a healthy diet.
- 33:42So we have to go to the animal studies.
- 33:44And that's where I think there's a lot of misinformation and
- 33:47confusion about fasting from the animal studies.
- 33:50So fasting is a longevity intervention when it is paired
- 33:55with caloric restriction. OK.
- 33:57When the animals make up for what they don't eat on the
- 34:00fasting days, there's little to no longevity benefit.
- 34:04So at least in laboratory animals, mice and rats, fasting
- 34:08per SE when it's isocaloric has little to no longevity effect.
- 34:13Fasting will absolutely turn down M Tor and in mice that
- 34:18happens pretty quickly. But I think people need to
- 34:20understand a 24 hour fast in a mouse is fundamentally different
- 34:25from a metabolic perspective than a 24 hour fast in a human.
- 34:28I don't know exactly. I don't think anybody knows
- 34:30exactly how the math works out, but it's probably more like a
- 34:33three or four day fast in a human in many ways, not in every
- 34:36way, but in many ways. So going from the animal studies
- 34:40to humans when it comes to fasting, I think it's just very
- 34:43risky. And it's, it's filled with a lot
- 34:44of misinformation. I think this is not.
- 34:47And so that's the data. My personal opinion is I would
- 34:51not which fasting from the perspective of fasting as a
- 34:54longevity intervention. I think for some people fasting
- 34:59can be a really powerful way to control body weight, to control
- 35:05overeating. And you need to be careful that
- 35:10you are eating a high quality diet if you're going to do
- 35:13regular fasting, right. I think that's an area where
- 35:15people often make mistakes, but I would not approach it from the
- 35:19perspective of longevity. And, and again, this is again
- 35:22getting in the weeds a little bit, but even the terminology is
- 35:25a little problematic because some people when they say
- 35:27fasting mean time restricted eating, like shrinking their
- 35:30meals down to 8 hours or 12 hours.
- 35:32Some people mean a 24 hour fast, some people mean a multi day
- 35:36water only fast. So those are all going to have
- 35:39different biological effects and people need to appreciate they
- 35:42are not biologically equivalent. I think all of them can be
- 35:46useful for certain people in certain conditions.
- 35:49Again, outside of caloric restriction, I don't think
- 35:52there's a lot of evidence that fasting is a longevity
- 35:56intervention. And again, this is maybe a
- 35:59useful counter to, to even rapamycin in the sense that, you
- 36:02know, I mentioned just because something slows aging in people
- 36:05doesn't mean it's going to make you live longer and healthier.
- 36:08I think caloric restriction, and this is speculation on my part,
- 36:10but I think caloric restriction falls into that category, at
- 36:13least the levels of caloric restriction that robustly slow
- 36:16aging in my 60% caloric restriction, 50% caloric
- 36:19restriction. I think in people, the data
- 36:21we've got, which is imperfect, but from things like epigenetic
- 36:24aging clocks and other biomarkers seem to show that
- 36:29caloric restriction slows aging in people biologically.
- 36:33And I think most people, if they were to practice that level of
- 36:36caloric restriction would not live longer.
- 36:38They certainly wouldn't live better.
- 36:40For most people, I don't think they'd actually live longer
- 36:43because mice in the laboratory don't die from frailty.
- 36:46They don't die from falls and fractures.
- 36:48They don't die from sarcopenia. But people practicing that level
- 36:52of caloric restriction, unless you really have the nutrition
- 36:55dialed in and you're really doing a lot of resistance
- 36:57training, are going to be at higher risk for those things.
- 37:00And so I think both from a quality and quantity of life
- 37:03perspective, the, I'm just going to call them side effects of
- 37:06caloric restriction are going to offset the benefits of slower
- 37:10solar biological agings. That may be a good at least
- 37:13thought experiment for why people can understand even if
- 37:16you're aging more slowly biologically, that may not mean
- 37:19you're going to live longer and be healthier in the long run.
- 37:23So sorry that was a big tangent. Yes, fasting mimics rapamycin,
- 37:28but they're not identical. So the other way I would think
- 37:30about it is that fasting or caloric restriction is going to
- 37:33have thousands of other biochemical effects that
- 37:36rapamycin doesn't have. Rapamycin is a very specific
- 37:39biochemical inhibitor of mtor. As far as we know it doesn't
- 37:43have any other major off target effects biochemically, whereas
- 37:46caloric restriction or fasting are going to completely rewire
- 37:51metabolism in ways that rapamycin doesn't.
- 37:53So I I think of them as overlapping but distinct.
- 37:57Rapamycin is very clean in the biochemical sense.
- 38:01Fasting and caloric restriction are very dirty in a biochemical
- 38:04sense. That's not meant to be a
- 38:05pejorative, it's just a sort of reflection of what's happening
- 38:08at the at the biochemical level. Can you also talk a little bit?
- 38:13I know this is not part of your expertise, but just a little bit
- 38:17because we hear so much now about what Klotho is and how it
- 38:21might relate to mtor. Sure.
- 38:24Yeah. So there there's definitely a
- 38:26so, So I think first of all macro level, I think of the
- 38:31biology of aging as a network of interacting proteins and
- 38:35metabolites and RNAs. And so there's this network of
- 38:38of factors that seem to modulate the rate of biological aging and
- 38:45the read out of that are the hallmarks of aging.
- 38:48Again, for that's an oversimplification, but for lack
- 38:50of a, you know, better way of saying it in, in a concise
- 38:53framework, the the action of that network is affecting the
- 38:58hallmarks of aging, which is what we perceive as biological
- 39:00aging. So Klotho and M4 are both in
- 39:02that network and they're, they both seem to be important, what
- 39:05I would call nodes in that network and also useful nodes.
- 39:08A useful node in the network is something we can target from an
- 39:11intervention perspective and we see that it has changes that we
- 39:15can measure on biological aging. Those changes being lifespan,
- 39:18health span metrics, epigenetic aging clocks, things like that.
- 39:22So Klotho is interesting. So, so Klotho, I think we know a
- 39:26lot less about Klotho and how it's working from a biochemical
- 39:29perspective to affect aging biology.
- 39:31It's what's called a transmembrane Co receptor for
- 39:34something called FGF 23, fibroblast growth factor 23.
- 39:38And it regulates a bunch of stuff including oxidative
- 39:40stress, IGF, one signaling, inflammation, all the things you
- 39:44would expect it to regulate if it's regulating biological
- 39:46aging. But I don't think we really
- 39:48understand how the data here is interesting.
- 39:51And and I think it's interesting that there's a lot, a lot of
- 39:53excitement about Klotho in the longevity community.
- 39:56But there's a lot less known about how it's working than
- 39:58there are for things like Rapamycin or AMP kinase or, you
- 40:01know, some of the other common players in in that network.
- 40:05So what we do know in mice is if a mouse is lacking Klotho, so
- 40:08you knockout Klotho in a mouse, it gets sick early, it dies
- 40:12early, and it seems to show some.
- 40:14Phenotypes of accelerated aging. So it's consistent with the idea
- 40:17that the mouse are are aging more rapidly and if you over
- 40:20express Klotho, the mice live longer.
- 40:22And this hasn't been looked at as extensively as it has with
- 40:26Emperor and rapamycin seem to be healthier across at least a few
- 40:29of the major organ and tissue systems, particularly brain,
- 40:33heart function things like that where people have done sort of
- 40:35deep dive. So that's certainly is
- 40:37consistent with the idea that Klotho is regulating biological
- 40:40aging. And we can move, you can change
- 40:42ageing either direction in laboratory animals.
- 40:44I think the cool thing about cloth though, is there's there's
- 40:47compelling human evidence that Klotho probably plays a role at
- 40:51least in health span and maybe in longevity in people.
- 40:54So lots of correlative studies showing that circulating Klotho
- 40:58levels are associated with health outcomes, cardiovascular
- 41:02disease, cognitive function, kidney disease.
- 41:04And there are people who have a variant of Klotho KLVSI think is
- 41:09the the. The the.
- 41:11The the variant designation that leads to higher levels of
- 41:15Klotho. So people who are heterozygotes
- 41:18for that variant, so they have higher levels of Klotho seem to
- 41:21also be protected against cardiovascular disease,
- 41:24dementia, and in a, in a couple of studies might even live a
- 41:27little bit longer. So that gives us an indication
- 41:31that Klotho may be important for human aging.
- 41:34So this has led to excitement around Klotho gene therapy,
- 41:38things like that. I think it's intriguing.
- 41:39I think we're getting pretty far ahead of the data to be talking
- 41:43about Klotho gene therapy at this point.
- 41:45And one of the cautionary notes is that there's at least some
- 41:48evidence that people who have two versions of this Klotho
- 41:50allele. So very high levels of Klotho
- 41:52might actually have shorter lifespan.
- 41:54So there's probably a sweet spot.
- 41:56And until we know what the sweet spot is, I'd be careful about
- 42:00putting in extra cloth though, you know, for the idea that it
- 42:02might have some, some benefited people.
- 42:04Again, super interesting research question.
- 42:07There are at least a couple of companies that are looking at
- 42:09ways to modulate Klotho activity, Klotho expression.
- 42:12So I think we'll start to see those things make their way
- 42:14through, you know, more traditional pipeline of
- 42:18intervention or drug development relationship to mtor.
- 42:21They interact with each other. You can find evidence both ways.
- 42:25So you can find evidence that more Klotho leads to inhibition
- 42:27of mtor, higher autophagy, which is one of the things that that
- 42:32mtor regulates. And also find some evidence that
- 42:34turning down mtor, at least the higher levels of circulating
- 42:36cloth, though. So again, I think at this point,
- 42:39my feeling is they're interacting with each other in
- 42:42this network, but we don't really understand the the the
- 42:44details of that interaction well enough to say a lot about
- 42:49exactly how that's working. I want to talk a little bit
- 42:52about big picture zoomed out and what actually moves the needle.
- 42:57You know, rapamycin is a prescription therapy that we're
- 43:01excited about in the longevity space.
- 43:03Patients are excited about supplements, but what actually
- 43:06moves the needle with health span?
- 43:09Yeah. So I think there's not a lot I
- 43:12would say outside of the kind of core that we can say for for the
- 43:15vast majority of people is going to move the needle.
- 43:17And so by the core, of course, we're going to start with
- 43:20lifestyle factors. I think about it and, and and
- 43:23Opti span, we sort of created this framework of four pillars
- 43:26of health span, but you can have 568 however you want to break it
- 43:30down. But but essentially it boils
- 43:31down to we use active words. So eat, move, sleep, connect.
- 43:35So nutrition, high quality diet, not necessarily caloric
- 43:38restriction, but high quality, not over nutrition, move
- 43:43exercise again, there's a lot to unpack in each of these and
- 43:46there's not A1 size fits all solution, but appropriate
- 43:49amounts of resistance training so you can maintain muscle mass,
- 43:52lean body mass, metabolic health.
- 43:54Also, you want to have cardiovascular training and
- 43:57biomarkers there like VO2 Max I think are really useful for for
- 44:01estimating where you're at. So exercise, sleep quality, sort
- 44:05of obvious on the surface, but that's a very individual thing.
- 44:09And I think, you know, some people don't struggle with
- 44:12sleep. A lot of people do.
- 44:13And with age, sleep quality seems to decline.
- 44:16Making sure you're getting adequate sleep and it's
- 44:17sufficient quality sleep. Super important.
- 44:20And then connect encompasses in my mind both sort of personal
- 44:24sense of purpose, mindfulness, but also the really important
- 44:28human relationship component. And I would say I think
- 44:31companion animals can play a role here too in terms of your
- 44:34feeling of connection to other beings, right?
- 44:38I think that's the one that scientists like me tend to
- 44:42underestimate the importance of. And I have completely done a 180
- 44:45on the connect pillar in the last three years compared to
- 44:48where I was as an academic. But I think a lot of people tend
- 44:51to underestimate the importance of that aspect of human
- 44:54relationships and feeling like you got a sense of purpose, like
- 44:58there's a reason why you're doing what you're doing.
- 44:59I think it's really important. Stress, of course, weaves
- 45:02throughout all of those pillars of health.
- 45:04Span and stress management is huge as a as a lever that can
- 45:09have a huge have an impact on, on your health.
- 45:12So outside of that, there are a few things that I would put as
- 45:15major levers for a lot of people, maybe most people
- 45:18dependent on on life stage. I would definitely put hormones
- 45:22in there. I think hormone, I'm going to
- 45:24use the word optimization. The problem is we don't really
- 45:27know what optimal is, but making sure your hormones aren't
- 45:30sufficiently dysregulated that it's leading to emotional or
- 45:34physical problems is hugely important.
- 45:37And that that is a big lever that a lot of people can pull
- 45:41and need to pull. In my opinion, once you get into
- 45:44to middle age. And obviously it's different in
- 45:46women and men and women have this thing called menopause,
- 45:49which as far as I know, it is 100% penetrant.
- 45:52Like every woman is going to get it.
- 45:54Men are different in that it's a lot.
- 45:56I mean, women are variable in menopause, don't get me wrong.
- 45:58But men I think are a lot more variable and what it looks like
- 46:02when you go through these hormonal changes that happen
- 46:04later in life, but super important for both men and and
- 46:07women. I blame everything on
- 46:09perimenopause. I think we're starting to learn,
- 46:13I mean, not everything, but I think we're starting to learn
- 46:16that there's a lot, a lot going on there in terms of accelerated
- 46:22health risks. And again, it's, it's sloppy
- 46:25terminology because we haven't proven it.
- 46:26But I think there are certainly a lot of arrows pointing to the
- 46:28idea that perimenopause and menopause lead to accelerated
- 46:34biological aging in in women. So, yeah, it's again way, way,
- 46:40way understudied, but people are starting to pay attention.
- 46:42And I think I'm encouraged that there's a lot of movement at
- 46:45least in the right direction. I think that the hardest thing
- 46:48for me about the the the female hormonal health situation is
- 46:53just that, you know, because of the Women's Health initiative
- 46:57and what happened as a result of that, we just kind of lost a
- 47:01generation of experts, right? And so now people are paying
- 47:04attention, but we'd be so much further ahead on understanding
- 47:07this if that hadn't happened. But it's good to see that things
- 47:10are starting to go the right direction there.
- 47:11And the, and I think the FDA removing the black box warning
- 47:14on hormone therapy for women is a step in the right direction as
- 47:17well. So I think there's reason for
- 47:18optimism, but yes, to me, that is the biggest lever most people
- 47:22can pull outside of the the lifestyle factors that the the
- 47:24pillars of health. And then I would say, you know,
- 47:27avoiding risky behaviors, not smoking, making sure you aren't
- 47:30drinking too much alcohol, sort of obvious, but but worth
- 47:32saying. And then I would say being
- 47:35proactive in your approach to health using the diagnostics
- 47:38that we have available. And again, this is where I think
- 47:41we obviously get into healthcare disparities, you know, but I do
- 47:44think there's a lot that the average person can do for one to
- 47:49$200 a month in the realm of proactive preventative medicine.
- 47:53I think that's about the 8020 right now.
- 47:55And people should do that because that's a big lever you
- 47:58can pull to make sure that you don't get sick or if you're on
- 48:01the path to disease, that you catch it early enough and you
- 48:04can take steps to get off that path.
- 48:07So those are the big levers that I can think of.
- 48:09I'm sure there are others, but but I guess the other place I
- 48:11would point that we tend not to think a lot about is mental
- 48:14health, right? And again, just evaluating,
- 48:16that's a big part of health and obviously it ties to physical
- 48:18health, but we kind of put it in this other bucket.
- 48:21So if you have mental health challenges, whether it's
- 48:25depression or anxiety, taking steps to get help and deal with
- 48:30that is another big lever that you can pull.
- 48:33And a lot of people do. And again, our culture is sort
- 48:36of creating this, you know, situation where just because of
- 48:41the nature of social media and what's happening in the world,
- 48:45you know, anxiety is an epidemic for sure.
- 48:48And so if you're struggling with that, there are lots of steps to
- 48:51take. That's getting to an area that
- 48:53I'm not an expert in. I've learned a lot, but there
- 48:56are lots of smart people who have advice on how to deal with
- 48:58anxiety and depression and other mental health challenges that
- 49:03people face. Being aware and taking action
- 49:06there I think is another big lever that people can pull.
- 49:09And then, and so those are the big things.
- 49:11And then we get into the incremental stuff.
- 49:13And there are some things that have incremental value, some
- 49:16supplements that I put in that bucket, particularly
- 49:19deficiencies that you can fix through supplementation, vitamin
- 49:22D, omega-3, that might even be in the, it's not a big lever for
- 49:25most people in my view, but it's sort of something, it's a no
- 49:27brainer. You should do it if you can
- 49:29measure it and you know that you're deficient.
- 49:31But then when we get into other supplements, there are some
- 49:33things I think have value, but I don't think they're going to
- 49:36really move the needle for for most people.
- 49:39And there are some things that are going to be individual.
- 49:41Like I said, rapamycin for me had a big effect.
- 49:44It had a big effect on my quality of life.
- 49:46I don't know if I'm going to live longer, but it had a big
- 49:48effect on my quality of life. I think there are people with
- 49:50things like rapamycin, SGLT, 2 inhibitors, things like that,
- 49:54where that becomes much more individual.
- 49:57It can have a big effect for that individual.
- 49:59But I don't think there's anything else, at least in the
- 50:01Jaro protective realm that I would point to that we should
- 50:03talk about for everybody at this.
- 50:05Point kind of in that vein, what are your pet peeves in the this
- 50:09field? What are the things that I think
- 50:10can get a lot of crap or get a lot of social media attention
- 50:14that really don't move the needle?
- 50:17Yeah, I mean, well, so we already talked about clocks.
- 50:20Clocks are one of my pet peeves, mostly because of the
- 50:24misinformation and, and the fact that they're being presented to
- 50:27people in a, in a way that isn't honest.
- 50:30I think honestly, the things that, that, that bother me the
- 50:33most tend to be the, the, the, the things that are being
- 50:37dishonestly represented to people and could be harmful to
- 50:42people, harmful being economic damage or health damage.
- 50:45So supplements are a big, big, big challenging space.
- 50:48Like I said, there are some supplements that I believe in.
- 50:50There are a lot of supplements where I'm just like, I don't
- 50:53know, maybe, maybe not. The problem in the supplement
- 50:57space, I think is the deceptive marketing.
- 50:59And I have yet to find a company that is selling longevity
- 51:02supplements that is not lying to consumers in my view, or at
- 51:05least deceiving them, intending to make them believe something
- 51:09that isn't true, even if the words themselves don't say
- 51:12something that isn't true. So deceptive marketing around
- 51:15supplements, I think is really, really problematic in this
- 51:17space. And most people are not equipped
- 51:19to be able to evaluate that. Related to that, I I am very
- 51:24concerned about academic scientists who are involved in
- 51:29selling biological age tests or supplements.
- 51:33I think that the general public will assume that somebody who
- 51:37has an affiliation at Harvard or MIT or pick your favorite
- 51:41university is giving credibility to the supplement or the test
- 51:47that they are selling. And then when that is
- 51:49deceptively marketed to consumers, in my view, that is
- 51:53unethical and a real problem from that perspective, but also
- 51:57because it makes the field look bad and and it creates A
- 51:59credibility problem for the field.
- 52:01So that's. Credibility as a whole when that
- 52:04happens, and I think that's we have to answer to patients when
- 52:09they've kind of been deceived by this supplement.
- 52:11I was told this would save my life.
- 52:13I saw this on TikTok so I bought it at 3:00 AM and.
- 52:18You know, in the academic world, I totally get it.
- 52:23We're not on the academic side. But there's plenty of physicians
- 52:26who have become spokespeople for various things, and they don't
- 52:31have any real evidence to back up what they're claiming, which
- 52:34makes it really tough for us to say no.
- 52:37I'm a doctor too, believe me, right?
- 52:41Yeah, no, I agree it is it's a real challenge.
- 52:43And I think obviously I don't have the answers for how you for
- 52:47how you have those conversations.
- 52:49I think helping people to recognize what is and isn't
- 52:53known and where the uncertainty begins and ends.
- 52:56I think is is probably the best we can do and then try to let
- 52:59people make their own decisions. But but also, I think pointing
- 53:03out when people, whether it's, you know, an academic, medical
- 53:08professional and influencer say things that are demonstrably
- 53:12untrue, pointing that out and then simply, you know, making
- 53:17the point, if somebody lies to you once, they're probably going
- 53:19to lie to you again. Why would you trust this person?
- 53:21And then it's up to people like they want to continue to trust
- 53:23these folks. That's on them in my view.
- 53:25Yeah, I, I think you're right. We touched a little bit earlier
- 53:29and you'd mentioned something about AI in this space and I
- 53:33wanted to get back to that. I know we've been leveraging it
- 53:38a little bit in how we do the work UPS on our patients and how
- 53:43we analyze the data that comes out of those work UPS.
- 53:46What are you most excited about, I guess, moving forward on how
- 53:50AI is going to change things for us?
- 53:52Because I think there is, I mean, there's broader
- 53:56implications on just healthcare in general and reducing red tape
- 54:00and stuff, but I mean specifically in the jurorscience
- 54:02field. Yeah.
- 54:04So there's lots of ways I think AI is going to impact
- 54:07geroscience, just like there's lots of ways it's going to
- 54:09impact every aspect of life. There are two that I think a lot
- 54:12about right now. 1 is on the research side, which is more
- 54:15around how these tools can enable us to interpret these
- 54:20very, very large data sets to identify either novel
- 54:24signatures, novel novel patterns or maybe even be hypothesis
- 54:28generating. And the clocks are an obvious
- 54:30example of this. This was before, you know that
- 54:32the the current batch of LLMS and how we see how powerful
- 54:35those are, but that's how the clocks were developed.
- 54:38It was was using AI tools to pick out the best in, in the
- 54:43Horvath clock case, 353 methylation sites out of
- 54:463,000,000. That's a clear example there.
- 54:49Even tools from 10 years ago were useful in identifying these
- 54:53novel predictive signatures for chronological age in that point.
- 54:57So those are going to just be continue.
- 54:59And as we start to generate larger human data sets from
- 55:03these large population studies, we need those AI tools to be
- 55:06able to interpret that data and identify correlations and
- 55:09signatures that would be really hard for individual human beings
- 55:12to to identify. So that's going to be 1 area,
- 55:15you know, intervention prediction, maybe using AI to,
- 55:19to look at what we know about the biology of aging and predict
- 55:21new drugs or other targets to go after to slow aging.
- 55:25That's gotten a lot of attention.
- 55:26So far I have not seen a single case where an AI predicted
- 55:30intervention proved out. Doesn't mean it's, it's not
- 55:32going to happen. I haven't seen any data.
- 55:35And my concern there is that the intervention set we're working
- 55:38with right now is so small and limited.
- 55:41If you put in, you know, rapamycin and SGLT 2 inhibitors
- 55:46and metformin, you're going to get out things that look like
- 55:49rapamycin. So we're going to find things
- 55:51that we already know about. I don't know yet that AI is
- 55:53going to be super powerful there.
- 55:55On the clinical side, the area that I I think about a lot and,
- 55:58and, and we're working on as are others is much what you
- 56:02described, right. So using these tools,
- 56:05particularly the advanced large language models to help us both
- 56:10integrate the data we're collecting from a whole bunch of
- 56:13different tests and diagnostics in the context of what's already
- 56:17clinically established to identify patterns and then
- 56:20report it back to the doctor and at some point the client in a
- 56:26way that is useful for them. I am, you know, we've been doing
- 56:30that for 18 months now since the, you know, the first sort of
- 56:34iteration of ChatGPT came out internally.
- 56:36We're not rolling this out to patients, at least initially.
- 56:39They weren't even close to being ready.
- 56:41But I have been. And you, this is probably your
- 56:42experience, too. I have been amazed at how good
- 56:45the tools have gotten. They're really, really good.
- 56:47They're not perfect, but human beings aren't perfect.
- 56:49So I definitely see a time in the pretty near future where we
- 56:55will have what I call AI Healthspan agents that can do
- 57:00exactly that, can take all of your data from the different
- 57:05diagnostics. Optimally, it'll be longitudinal
- 57:07data you've had over many months or years, integrate it, build in
- 57:13the wearables, the trackables, the real time data and give you
- 57:17feedback. And so again, this is where I
- 57:20think we kind of have to wait and see how the regulatory
- 57:22landscape evolves, how comfortable people are with the
- 57:25AI tools, how well the AI tools perform, to what extent will
- 57:30these tools be allowed to give medical recommendations?
- 57:33Right. At first, they're not going to
- 57:34be. And I think that's appropriate.
- 57:36They shouldn't be allowed to at first.
- 57:37I very much believe right now doctor in the loop is the only
- 57:41way to go. I am actually concerned about
- 57:43some of these direct to consumer companies that sell diagnostics
- 57:46to people and then don't give them any, any help after that.
- 57:49So that's a different topic. But I think there will come a
- 57:53time, and I don't know if it's five years from now, 10 years
- 57:55from now, two years from now, where people feel really, some
- 58:00people feel really, some people feel really comfortable with
- 58:02these tools now. I mean, I'm sure.
- 58:04I mean, I've put all my data into ChatGPT and said, hey, tell
- 58:07me what this means, right? So some people just take it as
- 58:10granted that ChatGPT is going to give you the right answer.
- 58:12You shouldn't do that right now. But there will come a time when
- 58:15it's pretty good. And so I don't know what that
- 58:18looks like, but I can see us get to a point where pretty pretty
- 58:20quickly, again, two years, five years, we've got these very
- 58:24powerful AI health span agents that can give you 24/7, 365
- 58:27feedback and we'll give you recommendations that are
- 58:31designed hopefully in partnership with your physician
- 58:34to optimize your health span. I don't think I, I see that path
- 58:39clear as day where that's going to happen.
- 58:41I just don't know how long it's going to take.
- 58:42And I don't know how the regulatory environment's going
- 58:46to, going to evolve. But optimally, you know, there
- 58:49will be a collection of physicians who really lean into
- 58:52these tools and can become the docs who can work in partnership
- 58:56with these tools, with the people who want to use them that
- 58:59way. The last thing I'll say on this,
- 59:01and again, maybe I'm being naive, but I, I, I, I hope not.
- 59:04I think that this is the opportunity to really deal so
- 59:07with some of the major healthcare disparities that we
- 59:09have right now. Because these tools are not
- 59:12prohibitively expensive. Everybody in principle should be
- 59:15able to have access to at least a rudimentary healthspan agent.
- 59:18Now, they may not all be able to have access to the best docs in
- 59:21the world who can help them use those tools, but I think it's
- 59:24going to be better than what most people get right now.
- 59:26And then it's going to be very much up to the individual.
- 59:29Do they want to use those tools and do they want to do the
- 59:31things that the tool tells them they need to do to optimize
- 59:36their health span? There's good obviously a huge
- 59:38behavior modification piece, but I do think this is a real
- 59:41opportunity to address a lot of the health healthcare
- 59:44disparities that are out there. It's not going to fix everything
- 59:46for sure, but I think it can, I think it can be a big help.
- 59:48So I'm I'm really excited about the where where things can go.
- 59:52I think you're right about that. Your last sentiment, it's
- 59:55interesting. I mean, it's not like people
- 59:57don't fundamentally understand that they should eat properly or
- 1:00:01exercise and sleep better and cut the alcohol.
- 1:00:04But having someone tell you exactly how to do those things
- 1:00:10is much more valuable. And.
- 1:00:13Why you're doing those things rather than just having the
- 1:00:16basic knowledge that smoking is bad and I should sleep 8 hours a
- 1:00:19night. And that's where this AI think
- 1:00:21does get interesting because it is pretty good at at giving you
- 1:00:26a plan. If you give it proper input
- 1:00:29data, it spits out a plan that can be pretty evidence based,
- 1:00:33and at least it's a good starting place for people, which
- 1:00:36I think is pretty interesting. And it's come a long way.
- 1:00:38We started two years ago and this, the technology, this
- 1:00:42wasn't even around. And each month it just gets
- 1:00:45better. Yeah, they upgrade Squad or
- 1:00:48ChatGPT and it's like Oh my gosh, this same thing took like
- 1:00:532 days three months ago and now it's doing it in we.
- 1:00:56Were like I wish it would do XY and Z and then two weeks.
- 1:00:59Later, Boom. It heard you.
- 1:01:01Yeah, yeah. The only thing I would add to
- 1:01:03that, I think you're right. Most people do in general know
- 1:01:06what they should be doing. But I think when it comes to the
- 1:01:08specifics, like you're saying, it helps to have somebody tell
- 1:01:10you in detail what you should be doing.
- 1:01:12I think when it comes to the specific, I'm still often
- 1:01:15surprised at how many people I don't know the things that I
- 1:01:19sort of take for granted right now that I'm, you know, I've
- 1:01:22been in this space for for a while.
- 1:01:23Even simple things like being able to read a nutrition label,
- 1:01:26walk through the store and understand, you know, where are
- 1:01:29the added sugars, right? Those are things where these AI
- 1:01:32tools also can be quite, quite helpful.
- 1:01:34And you know, again, depending on how you use them, potentially
- 1:01:38could tell you in the moment like, OK, that particular
- 1:01:42product is not aligned with your health goals.
- 1:01:46Why don't you consider this alternative, right?
- 1:01:48Or, you know, you're in your car, you're wearable, detects
- 1:01:51that you're blood pressure has spiked when we get, you know,
- 1:01:55continuous blood pressure monitors.
- 1:01:57And it's like, I can see that you seem to be stressed out.
- 1:02:00Perhaps you should consider deep breathing, you know, whatever
- 1:02:03the technique is. So the sort of just like in the
- 1:02:05moment, deescalate that sort of stress before it gets to the
- 1:02:09point that that, you know, it creates a, a major event for
- 1:02:12your day, or maybe even a major event in terms of a heart attack
- 1:02:16or something like that. So I think there's all sorts of
- 1:02:18ways this, this could evolve. People are going to be
- 1:02:20uncomfortable. Some people are going to be
- 1:02:21uncomfortable with the idea. Some people are going to be
- 1:02:23uncomfortable with the idea that the AI might be manipulating
- 1:02:26you. Like is it, is it controlling
- 1:02:28your behavior to get you to calm down?
- 1:02:29But I would argue that's probably a good thing If it's as
- 1:02:32long as it, I would think of it, it may be as more like emotional
- 1:02:34tuning. So I'm just, I'm interested to
- 1:02:37see how this evolves. But I but I think there's a lot
- 1:02:39of opportunities here. It's a benevolent AI.
- 1:02:41Yeah, hopefully. I always say thank you when I
- 1:02:45use ChatGPT because when they take over the world one day, I
- 1:02:49just want to be remembered as I was.
- 1:02:52I was always gracious. You're on their team.
- 1:02:53Yeah, you. Yelled it.
- 1:02:55There's all sorts of interesting human psychology and behavior
- 1:02:58that goes into to using these tools.
- 1:03:00Every once in a while, I find myself feeling a little
- 1:03:02embarrassed about the question I asked ChatGPT.
- 1:03:04And then I'm like, no, wait a minute, it's just a, it's just
- 1:03:06ChatGPT. I'm going to need to be
- 1:03:07embarrassed about it. There's so many different
- 1:03:09wearables right now. Are there ones that you use?
- 1:03:13I mean, I've used aura ring for sleep tracking.
- 1:03:15I personally found that with aura ring, I felt like there's
- 1:03:17about a six month value proposition there for me
- 1:03:20personally. And then I kind of knew what I,
- 1:03:21what I knew. I use my Apple Watch all the
- 1:03:23time to track, you know, my workouts and, and things like
- 1:03:26that. That's really the only wearable
- 1:03:28that I use a lot is my Apple Watch because it just does so,
- 1:03:32so much. But again, I think it's a very
- 1:03:34personal thing and, and what you, what you are most
- 1:03:37interested in, You know, I, if there was a really good, I think
- 1:03:42continuous blood pressure monitor, I'd, I have, I don't
- 1:03:44have blood pressure, I don't have high blood pressure.
- 1:03:46So it's not an issue for me, but I'd want to try it.
- 1:03:48I do like CGMI do do that periodically.
- 1:03:51I think that's a very useful behavior, educational and
- 1:03:54behavior modification tool. I don't think it's something
- 1:03:56people need to do all the time, continuous glucose monitoring,
- 1:03:59but I do it now. I do it maybe once every six
- 1:04:02months just to kind of, you know, see where I'm at.
- 1:04:04And I always learn something new every time I I use CGM.
- 1:04:09I'm kind of on the same page as you.
- 1:04:10I also like the latest the latest Airpods.
- 1:04:15You don't have to wear a heart rate monitor anymore because
- 1:04:18when you're exercising they're pretty good.
- 1:04:20I've attracted versus like a chest strap and it's almost
- 1:04:23identical data, so it's super helpful when I'm doing zone 2
- 1:04:28and zone 5 exercise. What other questions do you
- 1:04:30have? Can I tell you something?
- 1:04:32I'm going to delete this from the podcast.
- 1:04:34I had a dream last night about not that kind of dream and I
- 1:04:38woke up and I was like because he yelled at me in the dream and
- 1:04:41he's like why are you so nervous?
- 1:04:45Literally like had a nightmare. That that you yelled at her.
- 1:04:49No, they knew that I yelled at me.
- 1:04:52For being nervous. Or no, just in general.
- 1:04:55It was something like, I was so worried about the technology
- 1:04:58because we're good at seeing patients.
- 1:05:00I would say technology's not in our wheelhouse.
- 1:05:02Well, here you go, you can use this.
- 1:05:03What the hell is wrong with you? That's gonna be on the intro.
- 1:05:13That's great. I wanted to ask a little bit
- 1:05:16just because I know this is near and dear to your heart.
- 1:05:18With the dog aging project with NIA funding and everything
- 1:05:25getting messed up with the changes in government, where is
- 1:05:29it at right now and and what are the plans for when it's going to
- 1:05:34be completed? Sure.
- 1:05:36So first of all, may be useful to just define the dog aging
- 1:05:39project and the and the overarching goal.
- 1:05:41So there's really two parts to the dog aging project 1 is a
- 1:05:44large longitudinal study of aging.
- 1:05:46It's purely observational where we are just following dogs
- 1:05:49living with their owners and collecting as much data as we
- 1:05:52can about the dogs, mostly through owner surveys, some
- 1:05:55through veterinary records, some through biological samples.
- 1:05:57So genome, epigenome, metabolome, things like that.
- 1:06:01And that's about 50,000 some dogs in the longitudinal study
- 1:06:05today. Then there is the smaller
- 1:06:07clinical trial, which is a randomized double-blind
- 1:06:10placebo-controlled veterinary clinical trial of rapamycin that
- 1:06:13currently is about 250 dogs. It will eventually be more than
- 1:06:17500 dogs, half rapamycin, half placebo.
- 1:06:20There the goal is to determine does rapamycin increase lifespan
- 1:06:24and slow aging in dogs. So in the initial grant which
- 1:06:29was funded in 20 end of 2018, those two parts of the project
- 1:06:33were Co funded. They were both funded by the
- 1:06:35large grant from from NIA. That grant ended in 2023 and was
- 1:06:41not refunded. And you know, I have my feelings
- 1:06:45about that. As you can imagine, I would say
- 1:06:47lots of swear words if we talked about it.
- 1:06:49So we shouldn't talk about it. And, and, and it took a couple
- 1:06:52of years to get the clinical trial refunded.
- 1:06:54That has since been refunded. So that is enrolling.
- 1:06:58It's a five year grant. The trial will be done before
- 1:07:00the before the grant ends. So that is going to get
- 1:07:02completed. The longitudinal study has not
- 1:07:06yet been refunded. The grant was submitted a month
- 1:07:09or so ago. So fingers crossed, hopefully it
- 1:07:12will get refunded. We managed to keep the lights on
- 1:07:15through philanthropic funding. We have a nonprofit called the
- 1:07:17Dog Aging Institute. It's a 5O1C3 dog
- 1:07:21aginginstitute.org shameless plug if anybody wants to support
- 1:07:24it. So that kept the lights on and
- 1:07:25allowed us to keep at least the core team intact.
- 1:07:28So hopefully, like I said, the longitudinal study will be
- 1:07:31refunded and that will allow that project to to continue for
- 1:07:34another five years. The other thing I'll say on this
- 1:07:37topic and, and again, whether it's done through the dog aging
- 1:07:39project or in the private sector, I don't, I don't really
- 1:07:42care. I do think it is a a message I
- 1:07:45want to communicate to people that slowing aging in our
- 1:07:50companion animals is a solvable problem.
- 1:07:52In five years, we know probably 20 things that slow aging in
- 1:07:57laboratory animals and we can measure it.
- 1:07:59We know how to measure it. We can do this safely.
- 1:08:01We can test these things in companion animals.
- 1:08:03I can't say with 100% certainty, because I'm a scientist, that
- 1:08:06some of those are going to work in dogs, but some of those are
- 1:08:08going to work in dogs. It's going to be the case.
- 1:08:12We could solve that problem. This is just a resource
- 1:08:14allocation problem. If people care about their
- 1:08:16companion animals, we could do this.
- 1:08:19I don't know how much it would take, but it would take less
- 1:08:20than $100 million. That sounds like a lot of money.
- 1:08:23But if you look what we spend $100 million on crazy stuff all
- 1:08:27the time, that's a drop in the bucket.
- 1:08:29So this is all just to say this is this is only a resource
- 1:08:34allocation problem to increase healthy lifespan in our
- 1:08:37companion animals by 20 plus percent.
- 1:08:40Seems to me like it's a no brainer.
- 1:08:42Somebody needs to do this. Some rich person needs to get
- 1:08:44off your ass. If you care about your dog and
- 1:08:47do this, OK, That's my message. Any rich people listening, this
- 1:08:50is what you're going to do. Yeah, just imagine how much you
- 1:08:54would be beloved if you slowed aging in people's companion
- 1:08:57animals. This is worth it.
- 1:08:59Go do it. And I don't have to be involved,
- 1:09:02but I'm happy to tell you how to do it if you want to know.
- 1:09:04You know, dogs age faster or have a shorter lifespan than we
- 1:09:09do. So it's easier to track over a
- 1:09:13period of time than it is in humans.
- 1:09:15What other biometrics are are you going to be tracking in the
- 1:09:20in the intervention and the and the placebo group?
- 1:09:24Yeah. So two things to say about that.
- 1:09:26I'll talk about all the things we're measuring in a second.
- 1:09:28So you mentioned dogs age faster, which is absolutely
- 1:09:30true, right? The other piece that it makes
- 1:09:32dogs very powerful for this kind of a study is they share our
- 1:09:35environment, which we can't. We can't, you know, recapitulate
- 1:09:39in the laboratory. In fact, we try really hard not
- 1:09:40to. We try to control the
- 1:09:42environment. So that's another I think
- 1:09:43important aspect here that makes this informative about human
- 1:09:48biology as well. OK.
- 1:09:50So in the trial lifespan is the primary endpoint.
- 1:09:53So that is what we are statistically powered for.
- 1:09:56Again, this depends a little bit on the demography.
- 1:09:58And so that's it's a little bit of an estimate, but we believe
- 1:10:01we are statistically powered to detect a nine percent change in
- 1:10:03lifespan, which is towards the lower end of what's been
- 1:10:06reported for rapamycin in mice. So that's why we have the the
- 1:10:10size of the study and the enrollment criteria that we've
- 1:10:12got. That's the primary endpoint.
- 1:10:14Secondary endpoints include heart function measured by
- 1:10:17echocardiogram. That's because in mice, several
- 1:10:20labs have seen improvements in age-related heart function from
- 1:10:23rapamycin treatment, neurological function measured
- 1:10:26through a bunch of different neurological parameters,
- 1:10:29activity, disease incidents, and then we have exploratory
- 1:10:33endpoints. Oh, and cognitive function as
- 1:10:36well for secondary endpoint. Then we have exploratory
- 1:10:38endpoints looking at things like metabolome, microbiome,
- 1:10:42epigenome, blood chemistry, inflammatory markers, things
- 1:10:45like that. So we're trying to take as broad
- 1:10:49a look as we can given the constraints of working in
- 1:10:52companion animals and funding. So take as broad a look as we
- 1:10:56can at at Health Span. One of the challenges people
- 1:10:59often don't appreciate about doing these kinds of studies in
- 1:11:02dogs is that many of the reagents, I'm talking about
- 1:11:05things like antibodies or Elizas that we would use for
- 1:11:08quantitative measurements. We have them for humans and we
- 1:11:12have them for mice, but we don't have them for dogs.
- 1:11:14So there are things we would like to measure that we just
- 1:11:16can't measure in dogs because because the reagents haven't
- 1:11:19been generated for veterinary medicine.
- 1:11:20But the majority of things that we are interested in looking at,
- 1:11:23we can measure in it within the context of the clinical.
- 1:11:26That's pretty cool. I think we're going to be super
- 1:11:28excited to see the results once you're once you're done with
- 1:11:32full enrollment and you're getting down to that five year
- 1:11:34mark. And Everett, who doesn't love
- 1:11:36dogs? I mean, you would probably win a
- 1:11:39Nobel Peace Prize for. That there's someone else vying
- 1:11:43for. That I mean, yeah, I would just
- 1:11:45be, I would just be happy to like be able to demonstrate we
- 1:11:49can slow aging in ducks. And again, I mean, look,
- 1:11:51everybody's got an ego. I would love to be the person to
- 1:11:54do it, but honestly, I'll be happy when anybody does it.
- 1:11:56And I think that one of the things that has been really
- 1:11:59great is to see that the template that we built at the
- 1:12:03dog aging project is now starting to be moved into the
- 1:12:06private sector. So companies like Loyal that are
- 1:12:09going through the FDA approval process for aging in dogs.
- 1:12:13That's really encouraging and and exciting.
- 1:12:16And so like I said, this is a solvable problem.
- 1:12:18We'll get there. We could get there in a few
- 1:12:21years if people would actually put a relatively modest amount
- 1:12:25of resources towards this all. Right.
- 1:12:27Well, this was awesome. Yeah.
- 1:12:29Thank you so much. I.
- 1:12:30Enjoyed it you made our day truly.
- 1:12:32We appreciate you being such a prominent voice in the longevity
- 1:12:36space. I think there's a lot of
- 1:12:38charlatans and people with ulterior motives selling things
- 1:12:43and you brought so much credibility and just truth to a
- 1:12:47newer space and medicine and we're so grateful for that.
- 1:12:50So if our listeners who want to learn more about you, you're
- 1:12:54work, the Dog Aging project, want to know more, where can
- 1:12:57they find you? Yeah, so best place is the Opti
- 1:13:01Span podcast, which is on YouTube.
- 1:13:03OPTISPAN, it's optimal health span just mashed together, lots
- 1:13:08of content there. If you enjoyed this, there's
- 1:13:11plenty more where that came from.
- 1:13:12I'm also on Instagram at MK Rely.
- 1:13:15I'm also on X, but I'm not very active on on X these days at MK
- 1:13:18Rely. Dog Aging Project is Dog
- 1:13:21agingproject.org. If you have a dog, we're still
- 1:13:24enrolling dogs into the longitudinal study.
- 1:13:26So I'd absolutely encourage you, if you want to participate in
- 1:13:30Science of Longevity, nominate your dog to participate in the
- 1:13:34study. If your dog meets the criteria
- 1:13:36for the Rapamycin trial, we're still enrolling dogs into that
- 1:13:39as well. So you could potentially
- 1:13:41participate in the clinical trial as well and definitely
- 1:13:45would encourage anybody who's a dog lover to think about doing
- 1:13:48that. Geographically, where do they
- 1:13:50have to be? So in the United States, that's
- 1:13:53it, although we do have a limited number of clinical
- 1:13:55sites, there's about 21 or 22 at this point.
- 1:13:57So obviously it's easier if you live close to one of the
- 1:14:00clinical sites. So the dogs come in for the
- 1:14:02clinical trial once every six months.
- 1:14:04I should clarify though, that's only for dogs that are in the
- 1:14:07clinical trial. For dogs that are in the larger
- 1:14:09longitudinal study anywhere in the United States,
- 1:14:12unfortunately, it's not yet international.
- 1:14:14I wish it was. Someday we'll get there, but
- 1:14:16right now any dog in the United States can participate in the
- 1:14:19longitudinal study. And then there are eligibility
- 1:14:22requirements and geographic location near 1 of the clinical
- 1:14:26sites for the clinical trial. Awesome.
- 1:14:29Awesome, Matt. Thank you so much.
- 1:14:32You're welcome. We really appreciate you being
- 1:14:34kind of the adult in the room of the longevity.
- 1:14:37Spirit, I wish I could be the little kid in the room.
- 1:14:40There are days. Well, then we wouldn't need
- 1:14:43longevity, right? This has been awesome.
- 1:14:48Thank you so much. Hopefully we can have you back
- 1:14:50on at some point. Thank you, that's been a lot of
- 1:14:53fun. All right, all.
- 1:14:54Right, we'll let you know if Nisha has any more nightmares.
- 1:14:57Hopefully not. I don't enjoy being in people's
- 1:14:59nightmares. All right, take care.
- 1:15:00Take care guys. Thank you for playing the long
- 1:15:06game with MD Longevity Lab. You can visit us at
- 1:15:09www.mdlongevitylab.com to learn more about how we can support
- 1:15:14you on your journey. Stay connected with us on social
- 1:15:17media at MD Longevity Lab for tips, updates, and behind the
- 1:15:21scenes insights. If you enjoyed today's episode,
- 1:15:24we'd love it if you subscribe, left us a rating, or shared it
- 1:15:27with someone you know who's also playing the long game.
- 1:15:30Thanks for listening, We'll see you next time.